Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results

This is the phase Ib part of the phase I/II CAMILLA trial evaluating cabozantinib plus durvalumab in advanced chemo-refractory proficient mismatch repair or microsatellite stable (pMMR/MSS) gastrointestinal malignancies including gastric/gastroesophageal junction/esophageal (G/GEJ/E) adenocarcinoma,...

Descripción completa

Detalles Bibliográficos
Autores principales: Saeed, Anwaar, Park, Robin, Dai, Junqiang, Al-Rajabi, Raed, Kasi, Anup, Baranda, Joaquina, Williamson, Stephen, Saeed, Azhar, Ripp, Jacob, Collins, Zachary, Mulvaney, Kelly, Shugrue, Molly, Firth-Braun, Jeanette, Godwin, Andrew K., Madan, Rashna, Phadnis, Milind, Sun, Weijing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975105/
https://www.ncbi.nlm.nih.gov/pubmed/36702123
http://dx.doi.org/10.1016/j.xcrm.2023.100916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975105/
https://www.ncbi.nlm.nih.gov/pubmed/36702123
http://dx.doi.org/10.1016/j.xcrm.2023.100916

Ejemplares similares